

REMARKS

Claims 13-16 and 18-20 were rejected under 35 U.S.C. §102(b) as being anticipated by Gallagher ((U.S. 5,208,271).

Claims 13-16 and 18-20 have been cancelled.

The basis for this rejection has therefore been removed.

Claim 17 was rejected under 35 U.S.C. §103(a) as being unpatentable over Gallagher (U.S. 5,208,271) in view of Murray et al (U.S. 5,951,796).

Claim 17 has been cancelled.

The basis for this rejection has therefore been removed.

Claims 13-20 stand rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent 6,521,673.

Claims 13-20 have been cancelled.

The basis for this rejection has therefore been removed.


Claims 13-20 were also provisionally rejected under the judicially created doctrine of obviousness-type as being unpatentable over claims 1-46 of copending Application No. 10/326,338.

Claims 13-20 have been cancelled.

The basis for this rejection has therefore been removed.

In view of the above amendments and remarks, allowance of Claims 1-12 and 21 is respectfully requested.

Respectfully submitted,

By 
Lyndanne M. Whalen
Attorney for Applicant
Reg. No. 29,457

Bayer MaterialScience LLC
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741
(412) 777-3843
FACSIMILE PHONE NUMBER:
(412) 777-3902
s:\shared\jmf\LMW8686.amd